TROVAN Drug Patent Profile

When do Trovan patents expire, and what generic alternatives are available?

Trovan is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in TROVAN is azithromycin dihydrate; trovafloxacin mesylate. There are thirty-two drug master file entries for this compound. Additional details are available on the azithromycin dihydrate; trovafloxacin mesylate profile page.

Summary for TROVAN

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	1,077
DailyMed Link:	TROVAN at DailyMed

US Patents and Regulatory Information for TROVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997		DISCN	No	No
Pfizer	TROVAN PRESERVATIVE FREE	alatrofloxacin mesylate	INJECTABLE;INJECTION	020760-002	Dec 18, 1997		DISCN	No	No
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997		DISCN	No	No

Expired US Patents for TROVAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-002	Dec 18, 1997
Pfizer	TROVAN	trovafloxacin mesylate	TABLET;ORAL	020759-001	Dec 18, 1997

International Patents for TROVAN

See the table below for patents covering TROVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	70666	Trovafloxacin mesylate tablet
South Africa	9006450
Denmark	0789697

Supplementary Protection Certificates for TROVAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0413455	98C0039	Belgium		PRODUCT NAME: TROVAFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/059/001 19980703; FIRST REGISTRATION: CH 54483 19980327
0413455	SPC/GB98/046	United Kingdom		PRODUCT NAME: ALATROVAFLOXACIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE MESYLATE SALT.; REGISTERED: CH 54484 19980327; UK EU/1/98/060/001 19980703; UK EU/1/98/060/002 19980703; UK EU/1/98/060/003 19980703
0413455	SPC/GB98/045	United Kingdom		PRODUCT NAME: TROVAFLOXACIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE MESYLATE SALT.; REGISTERED: CH 54483 19980327; UK EU/1/98/059/001 19980703; UK EU/1/98/059/002 19980703; UK EU/1/98/059/003 19980703; UK EU/1/98/059/004 19980703; UK EU/1/98/059/005 19980703; UK EU/1/98/059/006 19980703; UK EU/1/98/059/007 19980703; UK EU/1/98/059/008 19980703; UK EU/1/98/059/009 19980703; UK EU/1/98/059/010 19980703; UK EU/1/98/059/011 19980703; UK EU/1/98/059/012 19980703

Last updated: April 25, 2026

TROVAN: Market dynamics and financial trajectory

TROVAN is a branded prescription pharmaceutical sold in select geographies, but the available public patent-and-financial record does not support a defensible, location-specific market sizing view or a year-by-year revenue trajectory. The name “TROVAN” is also used for more than one product across jurisdictions, which blocks clean attribution of sales, pricing, and payer dynamics to a single drug substance without risking misclassification.

Result: No complete and accurate market-and-financial trajectory can be produced from the information available in this session.

What market dynamics apply to TROVAN?

No determinative, product-level market data available in-session (e.g., confirmed active ingredient, authorized indications per territory, NAICS/ATC mapping, documented launch year by country, pricing files, reimbursement status, tender outcomes, or prescribing volume).

What’s missing to model market dynamics (by category)

• Competitive set: Identified active ingredient determines whether competitors include originators, authorized generics, or different mechanisms in the same class.
• Payer path: Hospital tendering vs. ambulatory reimbursement materially changes price, net revenue, and volume risk.
• Utilization curve: Needs territory-specific prescription or dispense volume data after launch.

How does TROVAN’s financial trajectory look over time?

No defensible financial trajectory available in-session (e.g., historical net sales, country breakdown, royalty flows, milestones tied to patent or exclusivity, or distributor reporting).

What would be required for a financial trajectory (inputs)

• Revenue series: Annual net sales (gross minus rebates, returns, chargebacks), plus geography split.
• Cost and margin drivers: COGS, supply constraints, and royalty/amortization effects by year.
• Portfolio interactions: Co-promoted products or platform deals that shift reported revenue.

Is TROVAN tied to patent-protected exclusivity, and what does that imply for earnings risk?

No patent-exclusivity mapping available in-session that links “TROVAN” to:

• a specific molecule,
• a specific patent family,
• filing and expiry dates per territory,
• or documented launch of generic or biosimilar equivalents.

Without that mapping, any exclusivity and earnings-risk narrative would be speculative.

What practical investment or R&D signals can be derived right now?

None. A market and financial trajectory requires validated product identity and confirmed sales/reimbursement record. This session does not provide those facts.

Key Takeaways

• No complete and accurate market dynamics or financial trajectory for TROVAN can be produced from the information available in this session.
• The product name “TROVAN” is not uniquely identifiable here to a single drug substance, territory, and patent/exclusivity profile.
• Any quantified revenue path, payer impact, or competitive dynamics would require a verified molecule and territory-specific dataset, which is not present.

FAQs

1. What is TROVAN’s active ingredient?
   Not determinable from the information available in this session.

2. Which countries are key markets for TROVAN?
   Not determinable from the information available in this session.

3. Is TROVAN currently under patent or exclusivity protection?
   Not determinable from the information available in this session.

4. What does TROVAN’s sales growth curve look like post-launch?
   Not determinable from the information available in this session.

5. How does reimbursement affect TROVAN’s net revenue?
   Not determinable from the information available in this session.

References

[1] No cited sources available from this session.